Neuroleptic malignant syndrome: Difference between revisions
m (Removed protection from "Neuroleptic malignant syndrome") |
No edit summary |
||
| Line 12: | Line 12: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{JH}} | ||
'''''Keywords and synonyms:''''' NMS | '''''Keywords and synonyms:''''' NMS | ||
==Overview== | ==Overview== | ||
'''Neuroleptic malignant syndrome (NMS)''' is a life-threatening, neurological | '''Neuroleptic malignant syndrome (NMS)''' is a life-threatening, neurological disorde most often caused by an adverse reaction to [[antipsychotic|neuroleptic or antipsychotic drugs]]. | ||
==Historical Perspective== | ==Historical Perspective== | ||
| Line 73: | Line 73: | ||
*Laboratory Values (WBC & CK) | *Laboratory Values (WBC & CK) | ||
==Diagnosis Criteria== | |||
===DSM-V Diagnostic Criteria for Paranoid Personality Disorder<ref name=DSMV>{{cite book | title = Diagnostic and statistical manual of mental disorders : DSM-5 | publisher = American Psychiatric Association | location = Washington, D.C | year = 2013 | isbn = 0890425558 }}</ref>=== | |||
{{cquote| | |||
* Patients have generally been exposed to a [[dopamine antagonist]] within 72 hours prior to symptom development. | |||
* [[Hyperthermia]] (>100.4°F or >38.0°C on at least two occasions, measured orally), associated with profuse [[diaphoresis]], is a distinguishing feature of neuroleptic malignant syndrome, setting it apart from other neurological side effects of anti psychotic medications. | |||
* Extreme elevations in temperature, reflecting a breakdown in central thermoregulation, are more likely to support the diagnosis of neuroleptic malignant syndrome. | |||
* Generalized rigidity, described as "lead pipe" in its most severe form and usually unresponsive to [[antiparkinsonian agents]], is a cardinal feature of the disorder and may be associated with other neurological symptoms (e.g., [[tremor]], [[sialorrhea]], [[akinesia]], [[dystonia]], [[trismus]], [[myoclonus]], [[dysarthria]], [[dysphagia]], [[rhabdomyolysis]]). | |||
* [[Creatine kinase]] elevation of at least four times the upper limit of normal is commonly seen. Changes in mental status, characterized by delirium or altered consciousness ranging from stupor to coma, are often an early sign. | |||
* Affected individuals may appear alert but dazed and unresponsive, consistent with catatonic stupor. Autonomic activation and instability manifested by tachycardia (rate >25% above baseline), [[diaphoresis]], [[blood pressure elevation]] (systolic or diastolic >25% above baseline) or fluctuation (>20 mmHg diastolic change or >25 mmHg systolic change within 24 hours), urinary incontinence, and pallor—may be seen at any time but provide an early clue to the diagnosis. | |||
* Tachypnea (rate >50% above baseline) is common, and respiratory distress—resulting from [[metabolic acidosis]], [[hyper metabolism]], chest wall restriction, [[aspiration pneumonia]], or [[pulmonary emboli]] can occur and lead to sudden respiratory arrest. | |||
* A workup, including laboratory investigation, to exclude other infectious, toxic, metabolic, and neuropsychiatric etiologies or complications is essential. | |||
* Although several laboratory abnormalities are associated with neuroleptic malignant syndrome, no single abnormality is specific to the diagnosis. | |||
* Individuals with neuroleptic malignant syndrome may have [[leukocytosis]], [[metabolic acidosis]], [[hypoxia]], decreased serum iron concentrations, and elevations [[serum muscle enzymes]] and [[catecholamines]]. | |||
* Findings from [[cerebrospinal fluid]] analysis and neuroimaging studies are generally normal, whereas [[electroencephalography]] shows generalized slowing. | |||
* Autopsy findings in fatal cases have been nonspecific and variable, depending on complications. | |||
}} | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 21:47, 3 November 2014
| Neuroleptic malignant syndrome | |
| ICD-10 | G21.0 |
|---|---|
| ICD-9 | 333.92 |
| DiseasesDB | 8968 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]
Keywords and synonyms: NMS
Overview
Neuroleptic malignant syndrome (NMS) is a life-threatening, neurological disorde most often caused by an adverse reaction to neuroleptic or antipsychotic drugs.
Historical Perspective
NLM was known about as early as 1956, shortly after the introduction of the first phenothiazines, and is derived from the French syndrome malin des neuroleptiques.[1]
Pathophysiology
The mechanism is thought to depend on decreased levels of dopamine due to:
- Dopamine receptor blockade
- Genetically reduced function of dopamine receptor D2[2]
Causes
NMS is caused almost exclusively by antipsychotics, including all types of neuroleptic medicines along with newer antipsychotic drugs.[3] The higher the dosage, the more common the occurrence. Rapid and large increases in dosage can also trigger the development of NMS. Other drugs, environmental or psychological factors, hereditary conditions, and specific demographics may cause greater risk, but to date no conclusive evidence has been found to support this. The disorder typically develops within two weeks of the initial treatment with the drug, but may develop at any time the drug is being taken. NMS may also occur in people taking a class of drugs known as dopaminergics when the dosage is reduced (i.e Levodopa).
Diagnosis
Symptoms
The first symptom to develop is usually muscular rigidity, followed by high fever and changes in cognitive functions. Other symptoms can vary, but may be unstable blood pressure, confusion, coma, delirium, muscle tremors, etc. Once symptoms do appear, they rapidly progress and can reach peak intensity in as little as three days. These symptoms can last anywhere from eight hours to forty days.
Laboratory Studies
A raised creatine phosphokinase (CPK) plasma concentration will be reported due to increased muscular activity. The patient may be hypertensive and suffering from a metabolic acidosis.
EEG Studies
A non-generalised slowing on an EEG is reported in around 50% of cases.
Unfortunately, symptoms of NMS are sometimes misinterpreted by doctors as symptoms of mental illness, delaying treatment.[4]
Mnemonic
A mnemonic used to remember the features of NMS is: FEVER.[5]
- F - Fever
- E - Encephalopathy
- V - Vitals unstable
- E - Elevated enzymes (elevated CPK)
- R - Rigidity of muscles
Prognosis
As with most illnesses, the prognosis is best when identified early and treated aggressively. In these cases NMS is usually not fatal, although there is currently no agreement on the exact mortality rate for the disorder. Studies have given the disorder a mortality rate as low as 5% and as high as 76%, although most studies agree that the correct percentage is in the lower spectrum, perhaps between 10% - 15%. Re-introduction to the drug that originally caused NMS to develop may also trigger a recurrence, although in most cases it does not.
Treatment
Although treatment is not always necessary, it will help to cure the disease and prevent fatal developments from occurring. The first step in treatment is generally to remove the patient from any neuroleptic or antipsychotic drugs being taken and to treat fever aggressively. Many cases require intensive care, or some kind of supportive care at the minimum. Depending on the severity of the case, patients may require other treatments to contend with specific effects of the disorder. These include circulatory and ventilatory support, the drugs dantrolene sodium, bromocriptine, apomorphine and electroconvulsive therapy (ECT) if medication fails.
Differential diagnosis
- Infection (sepsis, SIRS)
- Serotonergic syndrome
- Delirium tremens
- Heat Stroke
- Malignant hyperthermia
NMS and serotonergic syndrome
The clinical features of NMS and serotonergic syndrome are very similar. This can make differentiating them very difficult.[6]
Features, classically present in NMS, that are useful for differentiating the two syndromes are:[7]
- Fever
- Muscle rigidity
- Laboratory Values (WBC & CK)
Diagnosis Criteria
DSM-V Diagnostic Criteria for Paranoid Personality Disorder[8]
| “ |
|
” |
References
- ↑ Friedberg JM. Neuroleptic malignant syndrome. URL: [http://www.idiom.com /~drjohn/biblio.html http://www.idiom.com/~drjohn/biblio.html]. Accessed: July 3, 2006.
- ↑ Mihara K, Kondo T, Suzuki A; et al. (2003). "Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome". Am. J. Med. Genet. B Neuropsychiatr. Genet. 117 (1): 57–60. doi:10.1002/ajmg.b.10025. PMID 12555236.
- ↑ Theodore I. Benzer, MD, PhD (2005). "Neuroleptic Malignant Syndrome". Emedicine.
- ↑ Stacy Milbouer, "Quest for the truth", Nashua Telegraph http://www.nashuatelegraph.com/apps/pbcs.dll/article?AID=/20050424/NEWS01/104240081
- ↑ Identify neuroleptic malignant syndrome. schizophrenia.com URL: http://www.schizophrenia.com/sznews/archives/002054.html. Accessed: July 2, 2006.
- ↑ Christensen V, Glenthøj B (2001). "[Malignant neuroleptic syndrome or serotonergic syndrome]". Ugeskr Laeger. 163 (3): 301–2. PMID 11219110.
- ↑ Birmes P, Coppin D, Schmitt L, Lauque D (2003). "Serotonin syndrome: a brief review". CMAJ. 168 (11): 1439–42. PMID 12771076. Full Free Text.
- ↑ Diagnostic and statistical manual of mental disorders : DSM-5. Washington, D.C: American Psychiatric Association. 2013. ISBN 0890425558.
Template:Diseases of the nervous system
de:Malignes Neuroleptisches Syndrom nl:Maligne neuroleptica syndroom Template:WikiDoc Sources